Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 182 of 5804
-
New combo shows promise in Hormone-Sensitive breast cancer
Disease control CompletedRATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective tha…
Phase: PHASE3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Massive trial aims to find optimal Pre-Surgery combo for esophageal cancer
Disease control Recruiting nowEsophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious thera…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could a smart antibody boost chemo for head and neck cancer?
Disease control CompletedRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet know…
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a radioated molecule shrink untreatable neuroblastoma?
Disease control AVAILABLEThis is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).
Sponsor: Kieuhoa Vo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Supercharged t cells take on Hard-to-Treat cancers
Disease control AVAILABLEThe goal of this intermediate-size expanded access treatment program is to treat a subset of patients with advanced solid cancers, specifically pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), that express KRAS-G12D and the appropriate HLA with adoptive t-cell…
Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to tackle bipolar depression and suicidal thoughts
Disease control AVAILABLEThe purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide t…
Sponsor: NeuroRx, Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New stem cell processing method offers hope for patients without a perfect donor match
Disease control AVAILABLEThe primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threate…
Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Cow-Hemoglobin drug offers hope for anemia patients who refuse blood
Disease control NO_LONGER_AVAILABLEThe purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom allogeneic blood transfusion is not an option. HBOC 201 \[hemoglobin glutamer - 250 (bovine)\] has been previously studied as an alternative to blood transfusions …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New daily pill could help millions shed pounds and control diabetes
Disease control OngoingThe purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they wi…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New vaccine aims to protect infants from deadly diarrhea
⭐️ VACCINE ⭐️ CompletedIn this study, the tetravalent bioconjugate candidate vaccine Shigella4V will be tested to obtain first-in-human data on its safety and immunogenicity in infants and to identify the preferred dose of Shigella4V in 9 month old infants.
Phase: PHASE1, PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:03 UTC
-
Could a single sauna session lift depression and anxiety?
Symptom relief Not yet recruitingThis study aims to examine the scientific mechanisms of whole-body hyperthermia (WBH), a novel, rapidly acting, single session antidepressant and anxiolytic therapy. It also aims to determine its feasibility and acceptability in women with postpartum depression (PPD). The study w…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a stem cell shot before birth fix fanconi anemia?
Disease control Not yet recruitingThe investigators aim to evaluate the safety and efficacy of in utero hematopoietic stem cell transplantation (IUHSCT) for the treatment of fetuses diagnosed with Fanconi anemia (FA) during pregnancy.
Phase: PHASE1, PHASE2 • Sponsor: Agnieszka Czechowicz • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI could personalize emergency treatment for deadly aortic tears
Disease control Not yet recruitingAortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. Thi…
Phase: NA • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy before surgery shows promise for bile duct cancer
Disease control Not yet recruitingThis phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with intrahepatic cholangiocarcinoma that can be removed by surge…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets cancers missing key gene
Disease control Not yet recruitingThis phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the…
Phase: PHASE1, PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a pharmacist and text messages help smokers quit even when they're not ready?
Disease control Not yet recruitingThis study uses a factorial optimization experiment to identify which treatment components help adults who smoke and are not ready to quit in the next 30 days (smokers not ready to quit, or SNRTQ) achieve smoking cessation. Participants are recruited through Federally Qualified H…
Phase: NA • Sponsor: University of Virginia • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill combo aims to tame tough leukemia
Disease control Not yet recruitingThe goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML. The goal of Part 2 of this clinical research study is to learn if the …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug aims to stop rare blood disorder in its tracks
Disease control Not yet recruitingThis is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Magnetic brain zaps tailored to each patient may boost memory in Alzheimer's
Symptom relief Not yet recruitingBackground: Alzheimer's disease is a major health problem in our society. To date, pharmacological treatments to reduce Alzheimer's disease symptoms have obtained poor results and there is a growing interest in finding non-pharmacological treatments for this impactful disease. Tr…
Phase: NA • Sponsor: Universitat Oberta de Catalunya • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could a Pre-Surgery drug slash recurrence in rare joint tumors?
Disease control Not yet recruitingTenosynovial giant cell tumor (TGCT) is a rare neoplasm predominantly occurring in young and middle-aged adults, characterized by high recurrence and high disability rates. Surgery represents the first-line treatment at present. Although surgical resection can eradicate lesions, …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC